Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern

The concurrent prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV) raises the concern for the emergence of potential new β-CoV clades via genetic recombination, bearing high SARS-CoV-2-like transmissibility and high M...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Shan, Li, Weihua, Jiang, Shibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758279/
https://www.ncbi.nlm.nih.gov/pubmed/35125310
http://dx.doi.org/10.1016/j.it.2022.01.009
_version_ 1784632863605391360
author Su, Shan
Li, Weihua
Jiang, Shibo
author_facet Su, Shan
Li, Weihua
Jiang, Shibo
author_sort Su, Shan
collection PubMed
description The concurrent prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV) raises the concern for the emergence of potential new β-CoV clades via genetic recombination, bearing high SARS-CoV-2-like transmissibility and high MERS-CoV-like mortality rates. Therefore, we argue that there is an urgent need to develop pan-β-CoV vaccines that can target not only current SARS-CoV-2 variants of concern, but also future putative SARS-CoV-3- or MERS-CoV-2-like coronavirus.
format Online
Article
Text
id pubmed-8758279
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-87582792022-01-14 Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern Su, Shan Li, Weihua Jiang, Shibo Trends Immunol Forum The concurrent prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV) raises the concern for the emergence of potential new β-CoV clades via genetic recombination, bearing high SARS-CoV-2-like transmissibility and high MERS-CoV-like mortality rates. Therefore, we argue that there is an urgent need to develop pan-β-CoV vaccines that can target not only current SARS-CoV-2 variants of concern, but also future putative SARS-CoV-3- or MERS-CoV-2-like coronavirus. Elsevier Ltd. 2022-03 2022-01-14 /pmc/articles/PMC8758279/ /pubmed/35125310 http://dx.doi.org/10.1016/j.it.2022.01.009 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Forum
Su, Shan
Li, Weihua
Jiang, Shibo
Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
title Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
title_full Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
title_fullStr Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
title_full_unstemmed Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
title_short Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
title_sort developing pan-β-coronavirus vaccines against emerging sars-cov-2 variants of concern
topic Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758279/
https://www.ncbi.nlm.nih.gov/pubmed/35125310
http://dx.doi.org/10.1016/j.it.2022.01.009
work_keys_str_mv AT sushan developingpanbcoronavirusvaccinesagainstemergingsarscov2variantsofconcern
AT liweihua developingpanbcoronavirusvaccinesagainstemergingsarscov2variantsofconcern
AT jiangshibo developingpanbcoronavirusvaccinesagainstemergingsarscov2variantsofconcern

Ejemplares similares